Award notice Supplies

Sugammadex

Notice published in French. The AI analysis summarises it for you in your language.

Official notice and documents

Public buyer: Cliniques universitaires Saint Luc
Woluwe-Saint-Lambert
Place of performance: 1200 Woluwe-Saint-Lambert, Brussels-Capital
not published: buyer's address
Amount awarded: €126,000 excl. VAT
Planned end of contract: 23 July 2029
likely re-tender around January 2029
Bids received: 2
Form: Framework agreement
Multi-year contract: the buyer places orders as needs arise.
Procedure: Open procedure
Any company may submit a bid.
Publication: 5 August 2025
Notice language: French

AI analysis: go for it or not?

Summary in English, criteria, documents to provide and a GO / NO GO verdict in one minute.

Create my free account

Unlimited analyses during the 14-day Pro trial, no card needed.

Description

Le marché concerne les fournitures de la spécialité pharmaceutique contenant le principe actif « Sugammadex » pour injection en flacons « ready to use » de 200 mg/2 ml injectable.

Awarded to

Viatris BCE/KBO 0564.907.115

CPV codes

European codes that classify what the contract is about. They are how we find the tenders for your trade.

33661100

Similar contracts already awarded

Contract	Winner	Amount
Fingolimod (Chlorhydrate) Cliniques universitaires Saint Luc · 9 January 2026	AUROBINDO	€211,700
Sevofluraan AZ Delta vzw · 13 October 2026	Abbvie NV	€1,075,340
Raamovereenkomst voor het leveren van anesthetica Universitair Ziekenhuis Gent · 24 September 2026	PFIZER PFE BELGIUM SPRL Fresenius Kabi NV/SA ORION PHARMA BENELUX Grindeks Kalceks Belgium	€1,696,355
Raamovereenkomst voor het leveren van geneesmiddelen tegen pijn, koorts en osteo-articulaire aandoeningen Universitair Ziekenhuis Gent · 7 September 2026	Arega Pharma Fresenius Kabi NV/SA WillPharma Viatris bv	€1,516,053
Paracetamol IV AZ Delta vzw · 22 July 2026	B.Braun Medical NV	€298,570

Source : TED – Office des publications de l'Union européenne © Union européenne, données retraitées. Reference 512175-2025.